Cella D,Cappelleri JC,Bushmakin A,et al.Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treatedwith sunitinib versus interferon alfa[J].J Oncol Pract,2009,5(2):66-70.
[3]
Motzer RJ,Hutson TE,Tomczak P,et al.Sunitinib versus interferon alfa in metastatic renal-cell carcinoma[J].N Engl J Med,2007,356(2):115-124.
[4]
Faivre S,Delbaldo C,Vera K,et al.Safety,pharmacokinetic,and antitumor activity of SU11248,a novel oral multitarget tyrosine kinase inhibitor,in patients with cancer[J].J Clin Oncol,2006,24(1):25-35.
[5]
Castellano D,del Muro XG,Pérez-Gracia JL,et al.Patient-reported outcomes in a phase III,randomized study of sunitinib versus interferon-{alpha}as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population[J].Ann Oncol,2009,20(11):1 803-1 812.
